53 related articles for article (PubMed ID: 19895166)
1. Efficacy of single-agent bortezomib vs. single-agent thalidomide in patients with relapsed or refractory multiple myeloma: a systematic comparison.
Prince HM; Adena M; Smith DK; Hertel J
Eur J Haematol; 2007 Aug; 79(2):93-9. PubMed ID: 17608711
[TBL] [Abstract][Full Text] [Related]
2. Gain(1)(q21) is an unfavorable genetic prognostic factor for patients with relapsed multiple myeloma treated with thalidomide but not for those treated with bortezomib.
Smetana J; Berankova K; Zaoralova R; Nemec P; Greslikova H; Kupska R; Mikulasova A; Frohlich J; Sevcikova S; Zahradova L; Krejci M; Sandecka V; Almasi M; Kaisarova P; Melicharova H; Adam Z; Penka M; Jarkovsky J; Jurczyszyn A; Hajek R; Kuglik P
Clin Lymphoma Myeloma Leuk; 2013 Apr; 13(2):123-30. PubMed ID: 23291040
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of apoptotic index in multiple myeloma patients treated by conventional therapy and novel agents, thalidomide and bortezomib.
Minarik J; Scudla V; Ordeltova M; Bacovsky J; Pika T; Langova K
Eur J Haematol; 2009 Dec; 83(6):528-34. PubMed ID: 19624720
[TBL] [Abstract][Full Text] [Related]
4. Clinical assessment of bortezomib for multiple myeloma in comparison with thalidomide.
Satoh M; Oguro R; Yamanaka C; Takada K; Matsuura Y; Akiba T; Aotsuka N; Tani Y; Wakita H
J Pharm Pharm Sci; 2011; 14(1):78-89. PubMed ID: 21501555
[TBL] [Abstract][Full Text] [Related]
5. Sequential vincristine, adriamycin, dexamethasone (VAD) followed by bortezomib, thalidomide, dexamethasone (VTD) as induction, followed by high-dose therapy with autologous stem cell transplant and consolidation therapy with bortezomib for newly diagnosed multiple myeloma: results of a phase II trial.
Kim HJ; Yoon SS; Lee DS; Sohn SK; Eom HS; Lee JL; Chung JS; Kim K; Suh C; Won JH; Kim JS; Park JS; Kang HJ; Seong CM; Kim CS; Lee SJ; Lee JH
Ann Hematol; 2012 Feb; 91(2):249-56. PubMed ID: 21789621
[TBL] [Abstract][Full Text] [Related]
6. Thalidomide and bortezomib overcome the prognostic significance of proliferative index in multiple myeloma.
Minarik J; Scudla V; Bacovsky J; Zemanova M; Pika T; Ordeltova M; Langova K
Neoplasma; 2010; 57(1):8-14. PubMed ID: 19895166
[TBL] [Abstract][Full Text] [Related]
7. Diagnosis and the current trends in multiple myeloma therapy.
Dmoszyńska A
Pol Arch Med Wewn; 2008 Oct; 118(10):563-6. PubMed ID: 19112817
[TBL] [Abstract][Full Text] [Related]
8. Thalidomide, lenalidomide and bortezomib in the management of newly diagnosed multiple myeloma.
Laubach JP; Schlossman RL; Mitsiades CS; Anderson KC; Richardson PG
Expert Rev Hematol; 2011 Feb; 4(1):51-60. PubMed ID: 21322778
[TBL] [Abstract][Full Text] [Related]
9. [Current therapy for multiple myeloma].
Swieboda-Sadlej A
Pol Arch Med Wewn; 2005 Oct; 114(4):1030-6. PubMed ID: 16789532
[No Abstract] [Full Text] [Related]
10. Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature.
Badros A; Goloubeva O; Dalal JS; Can I; Thompson J; Rapoport AP; Heyman M; Akpek G; Fenton RG
Cancer; 2007 Sep; 110(5):1042-9. PubMed ID: 17654660
[TBL] [Abstract][Full Text] [Related]
11. Maintenance treatment in multiple myeloma.
Harousseau JL
Ann Oncol; 2008 Jun; 19 Suppl 4():iv54-5. PubMed ID: 18519405
[No Abstract] [Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
